ALK and lung carcinoma: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, erlotinib, icotinib and osimertinib, and anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-KIs), such as crizotinib, can target driver mutations and have been used in the treatment of lung carcinoma.